A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease

Movement Disorders

Volumn 30, Issue 3, 2015, Pages 427-431

  Reilmann, Ralf ^a,b,c   Rouzade Dominguez, Marie Laure ^d   Saft, Carsten ^e   Süssmuth, Sigurd D ^f   Priller, Josef ^g   Rosser, Anne ^h   Rickards, Hugh ⁱ   Schöls, Ludger ^c,j   Pezous, Nicole ^d   Gasparini, Fabrizio ^d   Johns, Donald ^k   Landwehrmeyer, Georg Bernhard ^f   Gomez Mancilla, Baltazar ^d,l  

^a George Huntington Institute   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

^e ST JOSEF HOSPITAL   (Germany)

^f UNIVERSITY OF ULM   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h CARDIFF UNIVERSITY   (United Kingdom)

ⁱ Department of Neuropsychiatry ^*  (United Kingdom)

^j GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^k NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^l MCGILL UNIVERSITY   (Canada)

more..

Author keywords

AFQ056; Chorea; Huntington's disease; MGluR5 antagonist

Indexed keywords

MAVOGLURANT; PLACEBO; AMINO ACID RECEPTOR BLOCKING AGENT; INDOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISORIENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FINGER TAPPING TEST; HUMAN; HUNTINGTON CHOREA; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNIFIED HUNTINGTON DISEASE RATING SCALE; ANALYSIS OF VARIANCE; CHOREA; CLINICAL TRIAL; COMPLICATION; DISABILITY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CHOREA; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; HUNTINGTON DISEASE; INDOLES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924599725     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26174     Document Type: Article

References (22)

1. Walker FO. Huntington's disease. Lancet 2007;369:218-228.
2. Smith MA, Brandt J, Shadmehr R. Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature 2000;403:544-549.
3. Grimbergen YA, Knol MJ, Bloem BR, Kremer BP, Roos RA, Munneke M. Falls and gait disturbances in Huntington's disease. Mov Disord 2008;23:970-976.
4. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-372.
5. Reilmann R. Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline. Mov Disord 2013;28:1030-1033.
6. André VM, Cepeda C, Levine MS. Dopamine and glutamate in Huntington's disease: A balancing act. CNS Neurosci Ther 2010;16:163-178.
7. Levandis G, Bazzini E, Armentero MT, Nappi G, Blandini F. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol Dis 2008;29:161-168.
8. Gubellini P, Eusebio A, Oueslati A, Melon C, Kerkerian-Le Goff L, Salin P. Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission. Eur J Neurosci 2006;24:1802-1814.
9. Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 2011;26:1243-1250.
10. Stocchi F, Rascol O, Destee A, et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord 2013;28:1838-1846.
11. Schiefer J, Sprunken A, Puls C, et al. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res 2004;1019:246-254.
12. Reilmann R, Bohlen S, Kirsten F, Ringelstein EB, Lange HW. Assessment of involuntary choreatic movements in Huntington's disease-toward objective and quantitative measures. Mov Disord 2011;26:2267-2273.
13. Bechtel N, Scahill RI, Rosas HD, et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology 2010;75:2150-2160.
14. Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012;11:42-53.
15. Reilmann R, Kirsten F, Quinn L, Henningsen H, Marder K, Gordon AM. Objective assessment of progression in Huntington's disease: a 3-year follow-up study. Neurology 2001;57:920-924.
16. Reilmann R, Bohlen S, Klopstock T, et al. Grasping premanifest Huntington's disease-shaping new endpoints for new trials. Mov Disord 2010;25:2858-2862.
17. Reilmann R, Bohlen S, Klopstock T, et al. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease. Mov Disord 2010;25:2195-2202.
18. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791-801.
19. Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10:31-42.
20. Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013;12:637-649.
21. Scahill RI, Hobbs NZ, Say MJ, et al. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Hum Brain Mapp 2013;34:519-529.
22. de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011;10:1049-1057.